.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,462,932

« Back to Dashboard

Claims for Patent: 5,462,932

Title: Oral liquid alendronate formulations
Abstract:Disclosed is a therapy protocol for treating and for preventing bone loss in patients who have difficulty in swallowing by administering a liquid formulation of alendronate which can be easily swallowed. Also described are pharmaceutical dosage forms of a syrup, aqueous solution, a solution formed from a reconstituted powder, of alendronate, for carrying out the therapeutic method.
Inventor(s): Brenner; Gerald S. (Norristown, PA), Katdare; Ashok V. (Norristown, PA), Pretzer; Denise (Chesterfield, MO), Whiteford; Donna T. (Brooklyn, NY)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/245,289
Patent Claims: 1. A pharmaceutical composition comprising a pharmaceutically effective amount of alendronate, in a pharmaceutically acceptable carrier and a sufficient amount of a buffer to maintain a pH of the composition in the range of 2 to 8 and complexing agent to prevent the precipitation of alendronate in aqueous solution.

2. The pharmaceutical composition of claim 2 being a liquid.

3. The pharmaceutical composition of claim 3, wherein said liquid is a syrup.

4. The pharmaceutical composition of claim 2, wherein said liquid is an aqueous solution.

5. The pharmaceutical composition of claim 1 being a powder for reconstitution.

6. The pharmaceutical composition of claim 5 dissolved in water.

7. The pharmaceutical composition of claim 1 wherein said alendronate is present in the amount of 0.0005 to 0.5 grams per gram of composition.

8. The pharmaceutical composition of claim 1 wherein said pharmaceutically acceptable excipient is purified water.

9. The pharmaceutical composition of claim 1 wherein said buffer is sodium citrate/citric acid, potassium hydrogen tartrate, sodium hydrogen tartrate, potassium dihydrogen phosphate, and disodium hydrogen phosphate.

10. The pharmaceutical composition of claim 1 wherein said buffer is present in an amount of 0.5 to 50 to 1 mole ratio of buffer:alendronate.

11. The pharmaceutical composition of claim 1 wherein said complexing agent is EDTA.

12. The pharmaceutical composition of claim 11 wherein said EDTA is present at a ratio of 0.005-2:1 parts by weight per part of alendronate by weight.

13. The pharmaceutical composition of claim 1 wherein said pH is in the range of 4-6.

14. The pharmaceutical composition of claim 1 being a syrup of the following formula:

15. The pharmaceutical composition of claim 14 being a syrup of the following formula:

16. The pharmaceutical composition of claim 1 being an aqueous solution of the following formula:

17. The pharmaceutical composition of claim 16 having the formula:

18. The pharmaceutical composition of claim 1 being a powder for reconstitution of the following formula:

19. A method for treating and/or preventing bone loss in a subject who has difficulty in swallowing, comprising administering a pharmaceutically effective dose of an oral liquid containing the alendronate pharmaceutical composition as defined in claim 1.

20. The method of claim 19, wherein said subject is human.

21. The method of claim 19, wherein the bone loss is osteoporosis-related, due to disuse, age-related, related to steroid therapy, rheumatoid-related, related to Paget's disease, or related to cancer.

22. The method of claim 19, wherein the treatment is prophylactic.

23. The method of claim 19, wherein said liquid is a syrup.

24. The method of claim 19, wherein said liquid is an aqueous solution.

25. The method of claim 19, wherein said liquid is an aqueous solution formed from a powder for reconstitution.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc